9270-25-R-RFIN-00020

The University of Mississippi's Department of Pharmaceutics and Drug Delivery at the School of Pharmacy is pursuing a sole source procurement for a BioAssemblyBot 400 Series 3D Bio-printer from Advanced Solutions Life Sciences, LLC. The procurement is specifically for an advanced bio fabrication system with a six-axis robotic arm, designed to support innovative pharmaceutical research in drug delivery systems, personalized medicine, and 3D bioprinting technologies. The equipment is unique in its ability to handle biological materials and produce consistent 3D biological structures with precise fabrication capabilities. This procurement opportunity is located in Lamar County, Mississippi, with a proposal due date of May 6, 2025, at 10:00 am Central Time. Interested parties may submit objections to the sole source certification to Jeff Wells at solesource@olemiss.edu before the stated deadline. The university has already negotiated a 5% discount with Advanced Solutions, highlighting potential long-term collaborative opportunities. The procurement process will require review and potential approval from the Public Procurement Review Board if no alternative sources are identified.

The procurement appears to be limited to a sole source vendor, with no explicit set-aside designations for disadvantaged enterprises mentioned in the documentation. Advanced Solutions Life Sciences, LLC is positioned as the exclusive manufacturer and distributor of the BioAssemblyBot 400 Series, with no alternative vendors identified. The procurement is specifically for the University of Mississippi and does not indicate broader competitive bidding. While a precise award value is not specified, the procurement involves a high-tech scientific instrument likely representing a significant capital investment for the university's pharmaceutical research infrastructure. The equipment will integrate into the Department of Pharmaceutics and Drug Delivery's existing research facilities, specifically supporting advanced biomedical research capabilities. The sole source nature of the procurement suggests that no competitive bidding will occur, and the university is seeking direct acquisition of this specialized scientific equipment. The procurement represents a targeted investment in cutting-edge biomedical research technology with potential implications for personalized medicine and drug delivery system development.